drugset / Trial / NCT04094961

Ixazomib + Pomalidomide + Dexamethasone In MM

NCT04094961

Phase 1/2 Active not recruiting 52 enrolled Omar Nadeem, MD Takeda · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I/II study using the combination of twice weekly ixazomib plus pomalidomide and dexamethasone in relapsed and or refractory multiple myeloma (RRMM) patients.

Timeline

Start
2019-09-18
Primary completion
2025-06-01
Completion
2027-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixazomib Unknown Oral
Background Dexamethasone Small molecule Oral
Background Pomalidomide Other / unclassified Oral

Indications